ETFs with REGN as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|9.17%||iShares NASDAQ Biotechnology Index Fund (IBB)||+46.33 (34.33%)|
|5.69%||PowerShares Dynamic Biotech &Genome (PBE)||+7.17 (31.88%)|
|5.25%||First Trust Amex Biotechnology Index Fund (FBT)||+14.07 (31.13%)|
|3.74%||Guggenheim S&P Midcap 400 Pure Growth ETF (RFG)||+7.53 (8.76%)|
|3.05%||First Trust Health Care AlphaDEX (FXH)||+3.86 (11.79%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron Pharmaceuticals, Inc., and actual events or results may differ materially from these forward-looking statements. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of EYLEA®, ZALTRAP®, and ARCALYST® and our product candidates, potential new indications for marketed products, and research and clinical programs now underway or planned; the likelihood and timing of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for marketed products; determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize EYLEA, ZALTRAP, and ARCALYST and other product and drug ... More ...